Nagorni-Obradović L
Institut za plućne bolesti i tuberkulozu, Univerzitetski klinicki centar, Beograd.
Med Pregl. 1993;46(11-12):429-33.
The paper presents the analysis of survival rate among 133 patients with squamous cell bronchial carcinoma during the five-year follow-up period, from 1985 to the end of 1989, treated at the Institute of Pulmonary Diseases and Tuberculosis in Belgrade. Duration of the survival was monitored in four therapeutical groups: B1 (surgically treated - 34 cases), B2 (conservatively treated using combined chemotherapy and irradiation therapy - 44 cases), B2-1 (treated with only chemotherapy - 32 cases) and B2-2 (treated with only irradiation therapy--23 cases). Maximal survival among the patients with squamous cell bronchial carcinoma was evidenced in surgically treated group of patients (8.8% survived for 5 years). Conservative therapy achieved three-year survival in 4.5% of group B2 patients and 9.4% of group B2-1 patients. Minimum survival was recorded in patients treated with a single irradiation therapy with maximal duration of 2 years achieved in 4.3% of cases. The mean duration of survival ranged from 28.1 +/- 15.2 months in group B1, being similar in groups B2 and B2-1 (15.3 +/- 8.0 and 15.1 +/- 8.2 months, respectively), while it was the least in the group B2-2: 8.8 +/- 6.4 months. Variance analysis revealed highly significant statistical difference in mean duration of survival among the patients with squamous cell bronchial carcinoma classified in different therapeutical groups (F = 107.783; p < 0.0001).
本文介绍了1985年至1989年底在贝尔格莱德肺病与结核病研究所接受治疗的133例支气管鳞状细胞癌患者在五年随访期内的生存率分析。在四个治疗组中监测了生存时间：B1组（手术治疗——34例）、B2组（采用联合化疗和放疗进行保守治疗——44例）、B2 - 1组（仅接受化疗治疗——32例）和B2 - 2组（仅接受放疗治疗——23例）。支气管鳞状细胞癌患者的最大生存率出现在手术治疗组患者中（8.8%存活5年）。保守治疗使B2组4.5%的患者和B2 - 1组9.4%的患者存活了三年。仅接受放疗治疗的患者生存率最低，4.3%的病例最长存活2年。B1组的平均生存时间为28.1±15.2个月，B2组和B2 - 1组相似（分别为15.3±8.0个月和15.1±8.2个月），而B2 - 2组最低：8.8±6.4个月。方差分析显示，不同治疗组的支气管鳞状细胞癌患者的平均生存时间存在高度显著的统计学差异（F = 107.783；p < 0.0001）。
